AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01618812 — intervention group
Intervention type: PROCEDURE
Intervention: Lateral lengthening osteotomy of calcaneus
Description: Use of artificial bone graft
Study NCT02296879 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SAIT301
Description: The treatment period will consist of 21-day cycles. On Day 1 of each cycle, SAIT301 will be administered as an intravenous (IV) infusion.
Study NCT01254955 — intervention group
Intervention type: BIOLOGICAL
Intervention: H1N1 vaccine Pandemrix
Study NCT03926546 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ERP for Individuals
Description: Comparing Group vs. Individual ERP for OCD
Study NCT03199339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TBA-7371
Description: The test product is TBA-7371 25 mg/ml oral suspension formulation and TBA-7371 matching placebo oral suspension.
Study NCT01390584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: IV
Study NCT01390584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: IV
Study NCT03749642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trazodone/gabapentin 5/50 mg
Description: The total daily doses administered will be trazodone 15 mg and gabapentin 150 mg.
Study NCT03749642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trazodone/gabapentin 10/100
Description: The total daily doses administered will be trazodone 30 mg and gabapentin 300 mg.
Study NCT03749642 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: The total daily doses administered will be:~* 600 mg from day 0 to day 6 (±1)~* 900 mg from day 7 (±1) to day 13 (±1)~* 1200 mg from day 14 (±1) to day 20 (±1)~* 1800 mg from day 21 (±1) to day 56 (±2)
Study NCT03749642 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Two capsules, three times a day, for 8 weeks.
Study NCT02385123 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine Inactivated
Description: A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain. Trivalent influenza vaccine is formulated annually, based on influenza strains projected to be prevalent in the upcoming flu season.
Study NCT01472237 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nutritional intervention
Description: Modification of diet
Study NCT01472237 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional intervention
Description: Modification of diet
Study NCT04498910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3451838
Description: Administered IV
Study NCT04498910 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV
Study NCT01108991 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity self-management
Description: This intervention includes a manual, telephone health coach calls, and automated telephone calls. The manual has 20 chapters for the active phase and 5 maintenance phase chapters. During the first 20 weeks the health coach will call patients every other week and the automated telephone calls will occur on the alternate weeks.
Study NCT01108991 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: COPD education + Usual care
Description: Six weeks of COPD self-management education plus usual care
Study NCT02557503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin and fluorouracil
Description: Oxaliplatin and fluorouracil by HAIC on with or without concomitant vascular invasion and extrahepatic metastases unresectable advanced primary liver cancer after TACE
Study NCT02756455 — intervention group
Intervention type: OTHER
Intervention: gastric cancer pts undergoing surgery
Description: Measure PCT (procalcitonin), CRP (C-reactive protein) and WBC (white blood cell count) in 3rd and 5th postoperative day and registration of all intra and postoperative complications
Study NCT03869892 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab control
Description: Concentrate for solution for infusion, Bevacizumab (7.5 mg/kg, IV) will be administered on Day 1 of each cycle.This treatment cycle will be repeated every 3 weeks.
Study NCT02611440 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care
Description: Initial interview with pharmacist (at the hospital discharge): Evaluation aimed to identify barriers to adherence to drug treatment followed by an information session on the disease, the benefit of drugs and the importance of diet and lifestyle habits. Pharmacist advices focused on how to take medication and how to manage adverse events will be provided.~Telephone interviews with hospital clinical pharmacist - patient (at M3 M6 and M9): The objective is to review with the patient its medication-taking routine and its potential difficulties, to motivate adherence to treatment and lifestyle/dietary rules, to give advices about therapeutics and how to take medication.~HCP contacts CP to determine the prescription refill. Final interview with HCP pharmacist (at M12): The objective is to take stock with the patient about its taking drug load.
Study NCT02649335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Propranolol will be started at a dose of 40 mg and will be titrated based on pulse rate with target of 55-60 beats per minute or 20-25% reduction in heart rate and maximum tolerated dose.If any patients develop intolerable side effects, they will be withdrawn from the study
Study NCT02649335 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic variceal ligation (EVL)
Description: Patients in EVL group will undergo regular sessions of UGIE with EVL till variceal eradication every 2- 4 weekly followed by 3 monthly for initial 6 months and 6 monthly in rest of the study period. If any patient develop acute variceal hemorrhage on follow up , will be treated inpatient with standard medical therapy(SMT) .
Study NCT04671485 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Patient undergoing radiotherapy for head and neck tumor with a compression mask, and assessed as anxious about wearing this mask will have standard care
Study NCT01390584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: IV
Study NCT03199339 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The test product is TBA-7371 25 mg/ml oral suspension formulation and TBA-7371 matching placebo oral suspension.
Study NCT01390584 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET
Description: fludeoxyglucose F 18 Imaging exam
Study NCT01390584 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: INRT
Description: selective external radiation therapy
Study NCT01390584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: IV
Study NCT00088998 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Study NCT01592695 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco quit line referral
Description: Participants assigned to this condition will receive a referral to their state tobacco quit line. The specific behavioral treatment that is provided will differ slightly depending upon the services available through the participant's state of residence.
Study NCT01592695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine replacement therapy - nicotine gum
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications
Study NCT01592695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy - nicotine gum
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications
Study NCT01390584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: IV
Study NCT00088998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Study NCT00088998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study NCT03398278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone Tamper Resistant
Description: Orally taking Oxycodone Tamper Resistant 40mg in fast state
Study NCT03398278 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OXYCONTIN®
Description: Orally taking OXYCONTIN® 40mg in fast state
Study NCT04671485 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Autohypnosis
Description: The patient will be called to learn autohypnosis during a specific consultation, with a radiotherapy manipulator trained to learn this technic.~The patient will use this technic during the centering scanner and the first 5 radiotherapy sessions
Study NCT04671485 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Musicotherapy
Description: the patient will choose the music he want to listen from a music database (3 specific moods).~The chosen music will be broadcast to the patient via a hi-fi system present in the treatment room during the centering scanner and for the first 5 radiotherapy sessions
Study NCT05124405 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: wearable activity tracker
Study NCT05095493 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc Acetate
Description: 50 mg tablet
Study NCT05095493 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Zinc Acetate matched placebo tablet
Study NCT05124405 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor
Description: wearable activity tracker
Study NCT01592695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine replacement therapy - nicotine lozenge
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications
Study NCT02125435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2408
Description: intravenous
Study NCT02125435 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenous
Study NCT04405102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanimod
Description: The investigational medical product (IMP) for this study is ozanimod. Ozanimod 0.23 mg be administered once daily for 4 days and then ozanimod 0.46 mg will be administered once daily for ten days.
Study NCT04405102 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: During hospitalization, patient will be given standard of care (Recommendations for standard of care management of COVID-19 will be provided for anticoagulation, fluid resuscitation, corticoids and other immunomodulators, antipyretics agents, antiviral agents and other treatments. These recommendations are subject to modifications based on the new literature data).
Study NCT04405102 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: During hospitalization, patient will be given standard of care (Recommendations for standard of care management of COVID-19 will be provided for anticoagulation, fluid resuscitation, corticoids and other immunomodulators, antipyretics agents, antiviral agents and other treatments. These recommendations are subject to modifications based on the new literature data).
Study NCT03146156 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: The lifestyle intervention is healthy eating (Medeterranian diet) and exercise to decrease weight by 5-7% compared to prepregnancy weight.
Study NCT01592695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy - nicotine lozenge
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications
Study NCT01592695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion Sustained Release
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications
Study NCT01390584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: May be given orally, IV push, or by IV infusion
Study NCT01390584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: IV
Study NCT01390584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Procarbazine
Description: PO
Study NCT01390584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: PO
Study NCT00066937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nortriptyline Oral Capsule
Description: Nortriptyline will be titrated up from 25 mg qhs to a maximum dose of 150 mg qhs based on treatment response and side effect profile.
Study NCT00066937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benztropine Oral Product
Description: Benztropine will be titrated up from .125 mg qhs to a maximum dose of .750 mg qhs based on treatment response and side effect profile.
Study NCT00066937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benztropine Oral Product
Description: Benztropine will be titrated up from .125 mg qhs to a maximum dose of .750 mg qhs based on treatment response and side effect profile.
Study NCT00066937 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: Six in-person, individual sessions of cognitive-behavioral therapy for pain management include relaxation training, pain coping skills training, cognitive therapy for negative and dysfunctional thoughts, and diaries for monitoring relaxation, goals, and negative thinking.
Study NCT00066937 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Disease MGT
Description: Six in-person, individual sessions of temporomandibular joint disorder (TMD) disease management (MGT) that include information about the jaw and good oral habits, diet, sleep, and general stress management.
Study NCT00066937 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Disease MGT
Description: Six in-person, individual sessions of temporomandibular joint disorder (TMD) disease management (MGT) that include information about the jaw and good oral habits, diet, sleep, and general stress management.
Study NCT02470767 — intervention group
Intervention type: DRUG
Intervention: Direct Oral Anticoagulant (DOAC)
Description: Treatment pattern following the summary of product characteristics
Study NCT02623439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant
Description: Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant
Study NCT02382900 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: quadrivalent human papillomavirus (types 6, 11, 16,18) recombinant vaccine
Description: dose scheme (0 and 6 month)
Study NCT02382900 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: quadrivalent human papillomavirus (types 6, 11, 16,18) recombinant vaccine
Description: dose scheme (0 and 6 month)
Study NCT00250575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clozapine
Study NCT01592695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion Sustained Release
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications
Study NCT01592695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications
Study NCT02127060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: for 1 month postoperative period, vitamin C was administered orally to the patients.
Study NCT01252888 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iStents
Description: Implantation of two iStents through a small temporal clear corneal incision
Study NCT01592695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications
Study NCT01592695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination pharmacotherapy - transdermal nicotine patch + nicotine gum
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications
Study NCT01592695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination pharmacotherapy - transdermal nicotine patch + nicotine gum
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications
Study NCT01592695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination pharmacotherapy - transdermal nicotine patch + nicotine lozenge
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications
Study NCT01592695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination pharmacotherapy - transdermal nicotine patch + nicotine lozenge
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications
Study NCT01592695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination pharmacotherapy - transdermal nicotine patch + bupropion
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications
Study NCT01592695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination pharmacotherapy - transdermal nicotine patch + bupropion
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications
Study NCT01506375 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gpASIT+TM
Description: 1 subcutaneous injection every 7 days during 29 days
Study NCT01592695 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol use risk reduction
Description: Participants engaging in risky alcohol use may receive this six-session telephone-based behavioral intervention for reducing alcohol use.
Study NCT01592695 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral activation for the treatment of depression
Description: Participants with elevated depressive symptoms may receive this six-session telephone-based behavioral activation intervention.
Study NCT02127060 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drug
Description: for 1 month postoperative period, placebo medication administered orally to the patients.
Study NCT04441866 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Automated algorithms
Description: Automated algorithms for measuring fetal biometry, and for the reconstruction of standard planes of fetal anatomy
Study NCT01592695 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral management of post-cessation weight gain
Description: Participants with concerns about gaining weight after quitting smoking may receive this six-session telephone-based behavioral self-management intervention designed to help attenuate post-cessation weight gain.
Study NCT03901599 — intervention group
Intervention type: OTHER
Intervention: Alveolar ventilation monitoring estimated by the capnographic ventilation
Description: Children are monitored using end-tidal CO2, Transcutaneous CO2 and volumetric capnographic. Respiratory rate is set using textbooks and guidelines (pediatric advanced life support). The physician in charge adapts the volume to target a CO2 between 38 and 42 mmHg. Data are recorded after a stabilization period of at least 5 minutes.
Study NCT01506375 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gpASIT+TM + adjuvant
Description: 1 subcutaneous injection every 7 days during 29 days
Study NCT01236807 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MR perfusion guidance
Description: Coronary revascularization guided by MR perfusion imaging
Study NCT01236807 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FFR guidance
Description: Coronary revascularization guided by invasive angiography and FFR
Study NCT03397758 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Study population
Description: First, periorbital area was treated with the short needles (exposure time 150ms, power 9W) to tighten the overlying dermis. Then, the fat pocket itself was treated additionally with the long needle (exposure time 400ms, power 9W).
Study NCT03599466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BF-Lisinopril Tablets 20mg
Description: BF-Lisinopril Tablets 20mg is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
Study NCT03599466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BF-Lisinopril Tablets 20mg
Description: BF-Lisinopril Tablets 20mg is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
Study NCT03599466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zestril Tab 20mg
Description: Zestril Tab 20mg will be used as a reference drug in this study